Literature DB >> 19910643

Altered plasma fibrin clot properties are associated with in-stent thrombosis.

Anetta Undas1, Jaroslaw Zalewski, Marek Krochin, Zbigniew Siudak, Marcin Sadowski, Jerzy Pregowski, Dariusz Dudek, Marianna Janion, Adam Witkowski, Krzysztof Zmudka.   

Abstract

OBJECTIVE: We sought to investigate whether patients with in-stent thrombosis (IST) display altered plasma fibrin clot properties. METHODS AND
RESULTS: We studied 47 definite IST patients, including 15 with acute, 26 subacute and 6 late IST, and 48 controls matched for demographics, cardiovascular risk factors, concomitant treatment and angiographic/stent parameters. Plasma clot permeability (K(s)), which indicates a pore size, turbidity (lag phase, indicating the rate of fibrin clot formation, DeltaAbs(max), maximum absorbance of a fibrin gel, reflecting the fiber thickness), lysis time (t(50%)) and maximum rate of D-dimer release from clots (D-D(rate)) were determined 2 to 73 (median 14.7) months after IST. Patients with IST had 21% lower K(s), 14% higher DeltaAbs(max), 11% lower D-D(rate), 30% longer t(50%) (all P<0.0001) and 5% shorter lag phase compared to controls (P=0.042). There were no correlations between clot variables and the time of IST or that from IST to blood sampling. Multiple regression analysis showed that K(s) (odds ratio=0.36 per 0.1 microm(2), P<0.001), D-D(rate) (odds ratio=0.16 per 0.01 mg/L/min, P<0.001) and stent length (odds ratio=1.1 per 1 mm, P=0.043) were independent predictors of IST (R(2)=0.58, P<0.001).
CONCLUSIONS: IST patients tend to form dense fibrin clots resistant to lysis, and altered plasma fibrin clot features might contribute to the occurrence of IST.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19910643     DOI: 10.1161/ATVBAHA.109.194936

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  21 in total

1.  Impaired fibrinolysis in degenerative mitral and aortic valve stenosis.

Authors:  Piotr Mazur; Jacek Myć; Joanna Natorska; Krzysztof Plens; Dariusz Plicner; Grzegorz Grudzień; Bogusław Kapelak; Anetta Undas
Journal:  J Thromb Thrombolysis       Date:  2018-08       Impact factor: 2.300

Review 2.  Introduction to haemostasis from a pharmacodynamic perspective.

Authors:  Cornelis Kluft; Jacobus Burggraaf
Journal:  Br J Clin Pharmacol       Date:  2011-10       Impact factor: 4.335

3.  Nanoparticle diffusion measures bulk clot permeability.

Authors:  Richard Chasen Spero; Rachel K Sircar; Ryan Schubert; Russell M Taylor; Alisa S Wolberg; Richard Superfine
Journal:  Biophys J       Date:  2011-08-17       Impact factor: 4.033

4.  Static axial stretching enhances the mechanical properties and cellular responses of fibrin microthreads.

Authors:  Jonathan M Grasman; Laura M Pumphrey; Melissa Dunphy; James Perez-Rogers; George D Pins
Journal:  Acta Biomater       Date:  2014-06-20       Impact factor: 8.947

5.  Characteristics of fibrin formation and clot stability in individuals with congenital type IIb protein C deficiency.

Authors:  J H Foley; L Ferris; K E Brummel-Ziedins
Journal:  Thromb Res       Date:  2012-01-13       Impact factor: 3.944

Review 6.  Fibrinogen and Fibrin in Hemostasis and Thrombosis.

Authors:  Sravya Kattula; James R Byrnes; Alisa S Wolberg
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-03       Impact factor: 8.311

Review 7.  Influence of cellular and plasma procoagulant activity on the fibrin network.

Authors:  Alisa S Wolberg; Maria M Aleman
Journal:  Thromb Res       Date:  2010-02-16       Impact factor: 3.944

8.  C-reactive protein and fibrin clot strength measured by thrombelastography after coronary stenting.

Authors:  Rolf P Kreutz; Janelle Owens; Jeffrey A Breall; Deshun Lu; Elisabeth von der Lohe; Islam Bolad; Anjan Sinha; David A Flockhart
Journal:  Blood Coagul Fibrinolysis       Date:  2013-04       Impact factor: 1.276

9.  Ex vivo properties of plasma clot formation and lysis in patients with cancer at risk for venous thromboembolism, arterial thrombosis, and death.

Authors:  Florian Posch; Stefanie Hofer; Johannes Thaler; Lena Hell; Oliver Königsbrügge; Ella Grilz; Lisa-Marie Mauracher; Johanna Gebhart; Christine Marosi; Bernd Jilma; Ingrid Pabinger; Cihan Ay
Journal:  Transl Res       Date:  2019-08-29       Impact factor: 7.012

10.  Type 2 diabetes as a modifier of fibrin clot properties in patients with coronary artery disease.

Authors:  Maciej Bochenek; Jaroslaw Zalewski; Jerzy Sadowski; Anetta Undas
Journal:  J Thromb Thrombolysis       Date:  2013-02       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.